search
Back to results

Video Assisted Pericardioscopic Surgery: Minimal-invasive Implantation of Epimyocardial Pacemaker Leads in Humans (VAPS)

Primary Purpose

Dysrhythmia, Cardiac, Heart Failure, Pacemaker Electrode Infection

Status
Unknown status
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
StingrayTM, Medtronic®
Sponsored by
RWTH Aachen University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dysrhythmia, Cardiac

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

This study will include patients who are planned to undergo a pacemaker therapy within their regular medical care and who are eligible for an alternative approach for lead placement (minimal-invasive pericardioscopic surgery):

I. Patients fulfilling current, sophisticated criteria for cardiac resynchronisation therapy (CRT) (e.g. patients with symptomatic heart failure independent of functional class, prolonged QRS-duration (especially left bundle branch block), severely depressed systolic left ventricular function), but have a history of failed CRT lead implantation or showed insufficient resynchronization after conventional CRT treatment, OR

II. Haemodialysis patients fulfilling the criteria for an implantation of a cardiac pacemakers due to bradycardiac dysrhythmia, OR

III. Patients suffering from acute pacemaker-lead-infection, who require system-explantation and concomitant implantation of a new system

Further inclusion criteria:

  1. Patients aged 18 years or above
  2. Adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel.
  3. Signed informed consent prior to study participation.

Exclusion Criteria:

  1. Euro Score II (http://www.euroscore.org/calc.html) > 20 %
  2. Patients in NYHA functional class IV
  3. Previous cardiac surgery / sternotomy
  4. Previous pericarditis
  5. Gender-independent myocardial wall thickness less than 5 mm
  6. Coexisting cardiac/vessel aneurysmata
  7. Patients with myocardial infarction within the last 4 weeks
  8. Pregnancy and breast-feeding
  9. Patients who are accommodated at judicial or official requests
  10. Patients with known anomalies of the cardiac anatomy
  11. Patients for whom beclometasone dipropionate is contraindicated
  12. Patients with bleeding disorders and coagulopathy
  13. Patients with a life expectancy below 12 months

Sites / Locations

  • University Hospital RWTH Aachen

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment

Arm Description

StingrayTM, Medtronic®

Outcomes

Primary Outcome Measures

Operative mortality
The mortality will be documented as in the usual clinical routine.

Secondary Outcome Measures

Moderate or severe operative complications
Operative complications (e.g. cardiac tamponade, severe bleeding, infection, lead dislodgement, pacing thresholds etc.) will be documented. Reduction of procedure-related postoperative complications, particular pulmonic complications in comparison to thoracotomy: Duration of mechanical ventilation Occurrence of pulmonary ventilation disorders: Atelectasis Pleural effusion Pneumothorax Postoperative pain obtained by visual analog pain scale
Adverse events
Adverse events will be documented
Overall survival
Overall survival will be documented as in the usual clinical routine.
Improvement of ejection mechanism
The acute and long-term effects of left-ventricular epimyocardial lead implantation/stimulation obtained by transthoracic echocardiography 1: Ejection fraction in percent, pre- and postoperative
Improvement of ventricle coordination
The acute and long-term effects of left-ventricular epimyocardial lead implantation/stimulation obtained by transthoracic echocardiography 2: Inter- and intraventricular delay in miliseconds, pre- and postoperative
Risk reduction of endocarditis in dialysis/infected patients
As compared to the literature

Full Information

First Posted
December 15, 2017
Last Updated
March 9, 2020
Sponsor
RWTH Aachen University
search

1. Study Identification

Unique Protocol Identification Number
NCT03387488
Brief Title
Video Assisted Pericardioscopic Surgery: Minimal-invasive Implantation of Epimyocardial Pacemaker Leads in Humans
Acronym
VAPS
Official Title
Video Assisted Pericardioscopic Surgery: Minimal-invasive Implantation of Epimyocardial Pacemaker Leads in Humans (VAPS - A Pilot Study)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Unknown status
Study Start Date
November 1, 2020 (Anticipated)
Primary Completion Date
February 10, 2022 (Anticipated)
Study Completion Date
March 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RWTH Aachen University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Particularly in CRT (Cardiac Resynchronisation Therapy), limited accessibility of the coronary sinus along with its branches and the mismatch between the region of latest left ventricular (LV) contraction and an adequate epimyocardial vein frequently lead to therapy failure and might even be responsible for the 30 % non-responders, although this aspect has not been thoroughly investigated yet. Further complications such as postoperative micro- (i.e. increased thresholds) or macro-dislodgement (i.e. loss of stimulation success) of the LV electrodes are frequent complications leading to reoperation or a change of strategy. The current transthoracic epimyocardial approach via mini-thoracotomy circumvents the aforesaid obstacles and is regarded as the first-choice alternative approach. Participation in the trial would prevent patients from this invasive, transthoracic approach and at the same time allow the same degree of freedom in lead placement. Risks and complications are in this case comparable to the open surgical approach but with a lower risk of intraoperative rib fracture, postoperative pain with consecutive pulmonary hypo-ventilation and pneumonia. Apart from the benefit of the single individual, societies benefit will include a much higher responder rate in CRT patients and less lead-associated infections. Thoracotomy with breach of the pleural cavity and single lung ventilation - a procedure that itself bears a high risk for postoperative atelectasis, pleural effusion and infection will be avoided. In patients on hemo-dialysis and patients who suffer from an infected pacemaker-system, extravascular lead placement should be preferred. Again, the current open, transthoracic epimyocardial approach via mini-thoracotomy is regarded as the first-choice alternative approach. Aim of this study is the validation of the feasibility of an alternative, minimal-invasive therapy method for implanting a cardiac pacemaker.
Detailed Description
Treatment: Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker leads Abridged Operation Protocol: 10 mm skin incision below the xiphoid process, blunt preparation towards the pericardial sac, insertion of the endoscope-carrying trocar, opening of the pericardium with endoscopic forceps, standardised inspection of the pericardial cavity, insertion of the bipolar Stingray® electrode via the endoscope working channel into pericardial space, implantation of the electrode into designated epimyocardial site under endoscopic vision, pacing measurements sensing, impedance, pacing threshold, interventricular delay (in CRT), panoramic fluoroscopy for future controls, retraction of the endoscope/trocar, subcutaneous tunnelling and connection of the respective electrode to: existing, infraclavicular CRT device, suture in layers, wound dressing a single- or dual-chamber pacemaker device implanted epigastrically, suture in layers, wound dressing

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dysrhythmia, Cardiac, Heart Failure, Pacemaker Electrode Infection, Hemodialysis-Induced Symptom, Bradycardia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
StingrayTM, Medtronic®
Intervention Type
Device
Intervention Name(s)
StingrayTM, Medtronic®
Other Intervention Name(s)
Clinical Investigational Lead Model 09090
Intervention Description
Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker lead model 09090, Medtronic®
Primary Outcome Measure Information:
Title
Operative mortality
Description
The mortality will be documented as in the usual clinical routine.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Moderate or severe operative complications
Description
Operative complications (e.g. cardiac tamponade, severe bleeding, infection, lead dislodgement, pacing thresholds etc.) will be documented. Reduction of procedure-related postoperative complications, particular pulmonic complications in comparison to thoracotomy: Duration of mechanical ventilation Occurrence of pulmonary ventilation disorders: Atelectasis Pleural effusion Pneumothorax Postoperative pain obtained by visual analog pain scale
Time Frame
7 days
Title
Adverse events
Description
Adverse events will be documented
Time Frame
12 months
Title
Overall survival
Description
Overall survival will be documented as in the usual clinical routine.
Time Frame
12 months
Title
Improvement of ejection mechanism
Description
The acute and long-term effects of left-ventricular epimyocardial lead implantation/stimulation obtained by transthoracic echocardiography 1: Ejection fraction in percent, pre- and postoperative
Time Frame
12 months
Title
Improvement of ventricle coordination
Description
The acute and long-term effects of left-ventricular epimyocardial lead implantation/stimulation obtained by transthoracic echocardiography 2: Inter- and intraventricular delay in miliseconds, pre- and postoperative
Time Frame
12 months
Title
Risk reduction of endocarditis in dialysis/infected patients
Description
As compared to the literature
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: This study will include patients who are planned to undergo a pacemaker therapy within their regular medical care and who are eligible for an alternative approach for lead placement (minimal-invasive pericardioscopic surgery): I. Patients fulfilling current, sophisticated criteria for cardiac resynchronisation therapy (CRT) (e.g. patients with symptomatic heart failure independent of functional class, prolonged QRS-duration (especially left bundle branch block), severely depressed systolic left ventricular function), but have a history of failed CRT lead implantation or showed insufficient resynchronization after conventional CRT treatment, OR II. Haemodialysis patients fulfilling the criteria for an implantation of a cardiac pacemakers due to bradycardiac dysrhythmia, OR III. Patients suffering from acute pacemaker-lead-infection, who require system-explantation and concomitant implantation of a new system Further inclusion criteria: Patients aged 18 years or above Adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel. Signed informed consent prior to study participation. Exclusion Criteria: Euro Score II (http://www.euroscore.org/calc.html) > 20 % Patients in NYHA functional class IV Previous cardiac surgery / sternotomy Previous pericarditis Gender-independent myocardial wall thickness less than 5 mm Coexisting cardiac/vessel aneurysmata Patients with myocardial infarction within the last 4 weeks Pregnancy and breast-feeding Patients who are accommodated at judicial or official requests Patients with known anomalies of the cardiac anatomy Patients for whom beclometasone dipropionate is contraindicated Patients with bleeding disorders and coagulopathy Patients with a life expectancy below 12 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nima Hatam, Dr. med.
Phone
+492418089221
Email
nhatam@ukaachen.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nima Hatam, Dr. med.
Organizational Affiliation
University Hospital RWTH Aachen
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital RWTH Aachen
City
Aachen
State/Province
NRW
ZIP/Postal Code
52074
Country
Germany
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nima Hatam, Dr. med.

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Video Assisted Pericardioscopic Surgery: Minimal-invasive Implantation of Epimyocardial Pacemaker Leads in Humans

We'll reach out to this number within 24 hrs